Vontobel Holding Ltd. Macrogenics Inc Transaction History

Vontobel Holding Ltd.

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Jun 03, 2024	BUY	$4.48 - $6.19 $154,577 - $213,579	34,504 Added 9.79%	387,001 $1.8 Million
Q3 2023 Oct 10, 2023	BUY	$4.48 - $6.19 $154,577 - $213,579	34,504 Added 9.79%	387,001 $1.8 Million
Q2 2023 Jun 03, 2024	BUY	$4.62 - $7.54 $1.63 Million - $2.66 Million	352,497 New	352,497 $1.89 Million
Q2 2023 Jul 24, 2023	BUY	$4.62 - $7.54 $1.63 Million - $2.66 Million	352,497 New	352,497 $1.89 Million
Q4 2022 Feb 14, 2023	BUY	$3.34 - $6.98 $668,734 - $1.4 Million	200,220 New	200,220 $1.34 Million

132

55.4M

215K

238K

Ticker MGNX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 61,458,800
Market Cap $200M
Description
MacroGenics, Inc., a biopharmaceutical company, develops and commercializes antibody-based therapeutics to treat cancer in the United States. Its approved product is MARGENZA (margetuximab-cmkb), a human epidermal growth factor receptor 2 (HER2) receptor antagonist indicated, in combination with chemotherapy, for the treatment of adult patients ...

Get notified when there are updates to the investment portfolio of Vontobel Holding Ltd., based on Form 13F filings with the SEC.

Stay updated on Vontobel Holding Ltd. with notifications on news.